This information is an update to the rosiglitazone prescribing information as GSK had submitted to the National Pharmaceutical Control Bureau, Ministry of Health Malaysia. This update relates to the use of rosiglitazone and rosiglitazone-containing products in patients with congestive heart failure as it relates to treatment of patients with Type 2 Diabetes Mellitus.
Initiation of rosiglitazone and rosiglitazone containing products are contraindicated in patients with NYHA Class III and IV heart failure. In addition, use of rosiglitazone containing products is not recommended in patients with symptomatic heart failure.
This update continues to reinforce that after initiation of rosiglitazone or rosiglitazone-containing products, or dose increases, patients should be monitored for signs and symptoms of adverse reactions relating to fluid retention, including heart failure. If symptoms of heart failure develop, these symptoms should be managed according to current standards of care and discontinuation or dose reduction of rosiglitazone must be considered.
Therefore, for those patients that just buy over the counter and of any queries, please consult your pharmacist and physician NOW!!!
No comments:
Post a Comment